The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

E. Boven, H. Schipper, C. A M Erkelens, S. A. Hatty, H. M. Pinedo

Research output: Contribution to journalArticlepeer-review

Abstract

The therapeutic efficacy of gemcitabine, a new nucleoside analogue, was assessed in a variety of well-established human soft tissue sarcoma and ovarian cancer xenografts grown s.c. in nude mice. Tumour lines selected had different histological subtypes, growth rates and sensitivities to conventional cytostatic agents. The three different doses and schedules designed on the basis of a mean weight loss between 5% and 15% were i.p. injections of daily 3.5 mg kg-1 × 4, every 3 days 120 mg kg-1 × 4, and weekly 240 mg kg-1 × 2, which ultimately resulted in 19%, 10% and 4% toxic deaths, respectively. The weekly schedule induced ≥ 50% growth inhibition in 2 4 soft tissue sarcoma and 4 6 ovarian cancer lines, while in three ovarian cancer lines ≥ 75% growth inhibition was obtained. The anti-tumour effects of gemcitabine appeared to be similar or even better than previous data with conventional drugs tested in the same tumour lines. In comparison with the every 3 days schedule, the weekly and the daily schedule were less effective in 5 7 and 3 3 tumour lines P-1 × 6 did not result in a significant increase in the percentages of growth inhibition when compared to lower doses of 120 mg kg-1 60 mg kg-1 in the same schedule. However, the 240 mg kg-1 weekly × 6 schedule showed superior effects in 2 3 tumour lines in comparison with the same dose given every 2 weeks × 3 (P

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalBritish Journal of Cancer
Volume68
Issue number1
StatePublished - Jul 1993
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer'. Together they form a unique fingerprint.

Cite this